ES2685503T3 - Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos - Google Patents
Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos Download PDFInfo
- Publication number
- ES2685503T3 ES2685503T3 ES09764426T ES09764426T ES2685503T3 ES 2685503 T3 ES2685503 T3 ES 2685503T3 ES 09764426 T ES09764426 T ES 09764426T ES 09764426 T ES09764426 T ES 09764426T ES 2685503 T3 ES2685503 T3 ES 2685503T3
- Authority
- ES
- Spain
- Prior art keywords
- vwf
- adamts13
- von willebrand
- cleavage fragments
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Método para analizar la eficacia de un factor de von Willebrand (FvW) utilizado en el tratamiento de la enfermedad de von Willebrand (EvW) en un individuo, que comprende medir fragmentos de división de FvW en una muestra de sangre del individuo antes y después del tratamiento, en el que un aumento de los fragmentos de división de FvW después del tratamiento indica que una desintegrina y metaloproteinasa con un motivo de trombospondina de tipo 1, miembro 13 (ADAMTS13) endógena en el individuo está dividiendo el FvW, y en el que una disminución o una ausencia de fragmentos de división de FvW después del tratamiento indica que la ADAMTS13 endógena en el sujeto no está dividiendo el FvW, y en el que los fragmentos de división de FvW son generados por la actividad de la ADAMTS13, y en el que la división de FvW se lleva a cabo bajo tensión de cizalladura.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12020208P | 2008-12-05 | 2008-12-05 | |
PCT/US2009/066588 WO2010065742A1 (en) | 2008-12-05 | 2009-12-03 | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2685503T3 true ES2685503T3 (es) | 2018-10-09 |
Family
ID=41682841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09764426T Active ES2685503T3 (es) | 2008-12-05 | 2009-12-03 | Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos |
Country Status (9)
Country | Link |
---|---|
US (6) | US8415114B2 (es) |
EP (2) | EP2358895B1 (es) |
JP (4) | JP6111016B2 (es) |
KR (1) | KR101670103B1 (es) |
AU (1) | AU2009322367B2 (es) |
CA (2) | CA2745805C (es) |
ES (1) | ES2685503T3 (es) |
PL (1) | PL2358895T3 (es) |
WO (1) | WO2010065742A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2358895B1 (en) * | 2008-12-05 | 2018-05-30 | Baxalta GmbH | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
US8637268B2 (en) * | 2010-11-17 | 2014-01-28 | Puget Sound Blood Center | Determination of von Willebrand Factor cleavage by ADAMTS13 |
KR102386584B1 (ko) | 2016-10-11 | 2022-04-14 | 래버러토리 코포레이션 오브 아메리카 홀딩스 | Adamts13 효소 활성을 결정하기 위한 방법 및 시스템 |
JP7120558B2 (ja) * | 2017-09-27 | 2022-08-17 | 国立大学法人東北大学 | せん断応力負荷時のフォンウィルブランド因子高分子マルチマーの保持率のインビトロ測定法 |
JP7359775B2 (ja) * | 2018-09-14 | 2023-10-11 | テルモ株式会社 | 循環器障害または血栓形成の進行またはそのリスクの予測 |
JP2022524291A (ja) * | 2019-02-01 | 2022-05-02 | 武田薬品工業株式会社 | 組換えVWF(rVWF)を使用する予防治療法 |
EP3999104A4 (en) * | 2019-06-07 | 2023-08-09 | Takeda Pharmaceutical Company Limited | USE OF RECOMBINANT ADAMTS13 TO TREAT SICKLE CELL DISEASE |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003284570A (ja) * | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
AU2002336367A1 (en) * | 2001-08-16 | 2003-03-03 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
DE20213920U1 (de) * | 2002-07-03 | 2003-01-16 | Boehm Martina | Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13 |
US7575872B2 (en) * | 2002-09-25 | 2009-08-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Antibody against von Willebrand factor cleaving enzyme and assay system using the same |
AU2002344102A1 (en) * | 2002-10-18 | 2004-05-04 | Japan As Represented By The President Of National Cardiovascular Center | Substrates specific to von willebrand factor cleaving protease and method of assaying the activity |
WO2005008241A1 (en) | 2003-07-07 | 2005-01-27 | University Of North Carolina At Chapel Hill | Method and system for detection of von willebrand factor (vwf) multimers |
US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
AU2006213411B2 (en) * | 2005-02-14 | 2010-09-23 | Alfresa Pharma Corporation | Antibody for assay of ADAMTS13 activity and method of activity assay |
WO2006133955A1 (en) * | 2005-06-17 | 2006-12-21 | Baxter International Inc. | Adamts13-comprising compositions having thrombolytic activity |
JP2007024839A (ja) | 2005-07-21 | 2007-02-01 | Sekisui Chem Co Ltd | 検体採取容器 |
US20090004673A1 (en) | 2006-01-31 | 2009-01-01 | Mitsubishi Kagaku Iatron, Inc. | Method for Determining Condition of Disseminated Intravascular Coagulation |
JP4820192B2 (ja) * | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのadamts13の測定と利用 |
CA2689121A1 (en) * | 2007-05-31 | 2008-12-11 | The Children's Hospital Of Philadelphia | Compositions and methods for modulation of adamts13 activity |
NZ609908A (en) * | 2008-10-27 | 2014-07-25 | Baxter Int | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
EP2358895B1 (en) * | 2008-12-05 | 2018-05-30 | Baxalta GmbH | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
BR112012006283B1 (pt) * | 2009-09-21 | 2022-03-15 | Takeda Pharmaceutical Company Limited | Formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e, usos de adamts13 |
EA035147B1 (ru) * | 2010-07-08 | 2020-05-06 | Баксалта Инкорпорейтид | Способ получения рекомбинантного adamts13 в культуре клеток |
US8637268B2 (en) * | 2010-11-17 | 2014-01-28 | Puget Sound Blood Center | Determination of von Willebrand Factor cleavage by ADAMTS13 |
-
2009
- 2009-12-03 EP EP09764426.4A patent/EP2358895B1/en active Active
- 2009-12-03 ES ES09764426T patent/ES2685503T3/es active Active
- 2009-12-03 CA CA2745805A patent/CA2745805C/en active Active
- 2009-12-03 KR KR1020117015378A patent/KR101670103B1/ko active IP Right Grant
- 2009-12-03 WO PCT/US2009/066588 patent/WO2010065742A1/en active Application Filing
- 2009-12-03 PL PL09764426T patent/PL2358895T3/pl unknown
- 2009-12-03 JP JP2011539696A patent/JP6111016B2/ja active Active
- 2009-12-03 AU AU2009322367A patent/AU2009322367B2/en active Active
- 2009-12-03 US US12/630,509 patent/US8415114B2/en active Active
- 2009-12-03 CA CA3098952A patent/CA3098952A1/en not_active Abandoned
- 2009-12-03 EP EP18173838.6A patent/EP3388529A1/en active Pending
-
2013
- 2013-03-12 US US13/795,214 patent/US8623612B2/en active Active
- 2013-11-12 US US14/078,324 patent/US9110085B2/en active Active
-
2014
- 2014-11-20 US US14/549,404 patent/US9488651B2/en active Active
-
2015
- 2015-07-03 JP JP2015134417A patent/JP2015213513A/ja not_active Withdrawn
-
2016
- 2016-11-07 US US15/345,070 patent/US10209263B2/en active Active
-
2017
- 2017-06-14 JP JP2017116794A patent/JP6691893B2/ja active Active
-
2019
- 2019-01-16 US US16/248,868 patent/US10900979B2/en active Active
- 2019-11-21 JP JP2019210455A patent/JP2020022515A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR101670103B1 (ko) | 2016-10-27 |
EP2358895A1 (en) | 2011-08-24 |
US20140154709A1 (en) | 2014-06-05 |
US8415114B2 (en) | 2013-04-09 |
PL2358895T3 (pl) | 2019-03-29 |
JP2015213513A (ja) | 2015-12-03 |
EP2358895B1 (en) | 2018-05-30 |
US20160033506A1 (en) | 2016-02-04 |
US20130252263A1 (en) | 2013-09-26 |
JP6111016B2 (ja) | 2017-04-05 |
US9110085B2 (en) | 2015-08-18 |
WO2010065742A1 (en) | 2010-06-10 |
CA2745805A1 (en) | 2010-06-10 |
US10900979B2 (en) | 2021-01-26 |
US20190145989A1 (en) | 2019-05-16 |
US8623612B2 (en) | 2014-01-07 |
JP2017153490A (ja) | 2017-09-07 |
US10209263B2 (en) | 2019-02-19 |
JP6691893B2 (ja) | 2020-05-13 |
AU2009322367A1 (en) | 2011-06-30 |
KR20110104940A (ko) | 2011-09-23 |
US20170153255A1 (en) | 2017-06-01 |
JP2020022515A (ja) | 2020-02-13 |
CA2745805C (en) | 2021-01-19 |
JP2012510817A (ja) | 2012-05-17 |
US20100143957A1 (en) | 2010-06-10 |
CA3098952A1 (en) | 2010-06-10 |
EP3388529A1 (en) | 2018-10-17 |
AU2009322367B2 (en) | 2015-03-26 |
US9488651B2 (en) | 2016-11-08 |
EP3388529A8 (en) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2685503T3 (es) | Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos | |
Phillip et al. | The mechanobiology of aging | |
AR058550A1 (es) | Analisis in vivo no invasivo, por impedancia bioelectrica de cambios en tejidos mediados por glucosa | |
AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
CL2017000546A1 (es) | Análisis de coagulación universal microfluídico basado en chips | |
ES2572372T3 (es) | Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1 | |
AR051524A1 (es) | Seleccion de pacientes para una terapia con un inhibidor de her | |
CR20110353A (es) | Compuestos de tiazolopiridina moduladores de sirtuina referencia cruzada | |
CR20120326A (es) | Dispositivo portátil de monitorización de la coagulación y método de evaluación de la respuesta de coagulación | |
ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
BR9914648A (pt) | Processo para monitorar ação medicamentosa deinibidor de proteasoma | |
PE20110565A1 (es) | Metodo de identificacion de factores de riesgo de la enfermedad | |
BRPI1005655A2 (pt) | Sistemas, dispositivos e métodos para medição do hematócrito de sangue integral com base na velocidade de preenchimento inicial | |
BR112015026222A2 (pt) | dispositivo de coleta de amostra de fluido biológico | |
ES2618506T3 (es) | Marcador epigenético para la identificación de linfocitos T CD3CD4 positivos | |
MD3529262T2 (ro) | Metode pentru promovarea răspunsului celulelor T | |
Draenert et al. | The prevalence of tooth hypersensitivity following periodontal therapy with special reference to root scaling. A systematic review of the literature. | |
CL2008003282A1 (es) | Poblacion de celulas humanas que expresan cd34 las cuales son obtenidas a partir de expansion de celulas de sangre de cordon umbilical en presencia de celulas menstruales humanas, metodo para obtener dichas celulas. | |
PE20190517A1 (es) | Preparacion farmaceutica antienvejecimiento | |
BR112014015424A2 (pt) | detecção de células derivadas de tecido do cordão umbilical humano | |
BR112015021507A2 (pt) | métodos e composições para o diagnóstico de pré-eclampsia | |
ES2603616T3 (es) | Aparato, método y medio de almacenamiento legible por ordenador para evaluar el estado fisiológico de un paciente | |
Mancinelli et al. | Age-associated declining of the regeneration potential of skeletal stem/progenitor cells | |
CY1114910T1 (el) | Βιοδεικτης για παρακολουθηση ασθενων | |
Ozsoy et al. | Effects of cavity disinfectants on bond strength of an etch-and-rinse adhesive to water-or ethanol-saturated sound and caries-affected dentin |